Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
April 3, 2025
This regulatory endorsement further underscores the broader applicability of GLP-1 agonists beyond diabetes management
If deemed ineligible after your Nexa provider consultation, you receive a full refund.
is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history
US$ 20.36
US$ 25.61
US$ 24.32
US$ 29.39
